LONDON (MarketWatch) -- Human Genome Sciences said a Phase 2 trial of its LymphoStat-B showed it significantly reduced disease activity across multiple clinical measures against systemic lupus ...
“The European approval of Benlysta represents a significant milestone, and we are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with ...
NEW YORK (MarketWatch) -- Human Genome Sciences, Inc. unit CoGenesys and PDL BioPharma, Inc. inked a worldwide licensing agreement that provides PDL rights to intellectual property for an undisclosed ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Stock in Rockville-based Human Genome Sciences Inc. <a href ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. British drug maker GlaxoSmithKline, which owns St. Louis ...
(Reuters) - Human Genome Sciences Inc posted a wider-than-expected quarterly loss, hurt by lower sales of its lupus drug Benlysta, sending its shares down 9 percent after market. Human Genome also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results